Yue Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yue Hu has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
B. Michael Ghadimi
7 shared publications- Elisabeth Hessmann
University Medical Center Göttingen 7 Clinical Research Unit 5002, KFO5002 Göttingen, Germany
7 shared publications - Frank Kramer
Faculty of Applied Computer Science, University of Augsburg
7 shared publications Georg Emons
7 shared publicationsHendrik A. Wolff
7 shared publicationsHenry Du
Department of Chemical Engineering and Materials Sciences, Stevens Institute of Technology, Hoboken, NJ, USA
7 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling
Schematic model of the chemoradiation treatment after Wnt-3a stimulation.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling
Schematic model of the chemoradiation treatment after Wnt-3a stimulation.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling
Experimental conditions for cellular viability assays and dual luciferase reporter assays.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling
Experimental conditions for cellular viability assays and dual luciferase reporter assays.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S2 from Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling
Experimental conditions for colony formation assays.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling
Experimental conditions for colony formation assays.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Figure S5 from Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling
Schematic model for (A) the generation of radiation resistant SW1463RES and (B) whole genome expression profiling experiments.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling
Schematic model for (A) the generation of radiation resistant SW1463RES and (B) whole genome expression profiling experiments.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S5 from Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling
Plating efficiencies of cells before and after treatment with siRNAs and XAV-939, stimulation with Wnt-3a, overexpression of mutated β-catenin (S33Y) and SW1463 becoming radiation resistant. (A) Plating efficiencies for RT, (B) plating efficiencies for CRT.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling
Plating efficiencies of cells before and after treatment with siRNAs and XAV-939, stimulation with Wnt-3a, overexpression of mutated β-catenin (S33Y) and SW1463 becoming radiation resistant. (A) Plating efficiencies for RT, (B) plating efficiencies for CRT.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S4 from Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling
Experimental conditions for Western blot analyses.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling
Experimental conditions for Western blot analyses.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Table S6 from Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling
(A) Significantly upregulated Wnt genes comparing SW1463RES to SW1463. Differentially expressed genes (B) between SW1463, and SW1463 six hours after exposure to a single dose of 4 Gy of X-rays (SW1463-4 Gy). Differentially expressed genes (C) between SW1463RES, and SW1463RES six hours after exposure to a single dose of 4 Gy of X-rays (SW1463RES-4 Gy).
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Chemoradiotherapy Resistance in Colorectal Cancer Cells is Mediated by Wnt/β-catenin Signaling
(A) Significantly upregulated Wnt genes comparing SW1463RES to SW1463. Differentially expressed genes (B) between SW1463, and SW1463 six hours after exposure to a single dose of 4 Gy of X-rays (SW1463-4 Gy). Differentially expressed genes (C) between SW1463RES, and SW1463RES six hours after exposure to a single dose of 4 Gy of X-rays (SW1463RES-4 Gy).
- Open Access
Probing Three-Dimensional Magnetic Fields: I -- Polarized Dust Emission
Polarized dust emission is widely used to trace the plane-of-the-sky (POS) component of interstellar magnetic fields in two dimensions. Its potential to access three-dimensional magnetic fields, including the inclination angle of the magnetic fields relative to the line-of-sight (LOS), is crucial for a variety of astrophysical problems. Based on the statistical features of observed polarization fraction and POS Alfv\'en Mach number $\overline{M_{\rm A}}_{,\bot}$ distribution, we present a new method for estimating the inclination angle. The magnetic field fluctuations raised by anisotropic magnetohydrodynamic (MHD) turbulence are taken into account in our method. By using synthetic dust emission generated from 3D compressible MHD turbulence simulations, we show that the fluctuations are preferentially perpendicular to the mean magnetic field. We find the inclination angle is the major agent for depolarization, while fluctuations of magnetic field strength and density have an insignificant contribution. We propose and demonstrate that the mean inclination angle over a region of interest can be calculated from the polarization fraction in a strongly magnetized reference position, where $\overline{M_{\rm A}}_{,\bot}^2\ll1$. We test and show that the new method can trace the 3D magnetic fields in sub-Alfv\'enic, trans-Alfv\'enic, and moderately super-Alfv\'enic conditions ($0.4\lesssim M_{\rm A}\lesssim1.2$). We numerically quantify that the difference between the estimated inclination angle and actual inclination angle ranges from 0 to $20^\circ$ with a median value of $\le10^\circ$.Open AccessProbing Three-Dimensional Magnetic Fields: I -- Polarized Dust Emission
Polarized dust emission is widely used to trace the plane-of-the-sky (POS) component of interstellar magnetic fields in two dimensions. Its potential to access three-dimensional magnetic fields, including the inclination angle of the magnetic fields relative to the line-of-sight (LOS), is crucial for a variety of astrophysical problems. Based on the statistical features of observed polarization fraction and POS Alfv\'en Mach number $\overline{M_{\rm A}}_{,\bot}$ distribution, we present a new method for estimating the inclination angle. The magnetic field fluctuations raised by anisotropic magnetohydrodynamic (MHD) turbulence are taken into account in our method. By using synthetic dust emission generated from 3D compressible MHD turbulence simulations, we show that the fluctuations are preferentially perpendicular to the mean magnetic field. We find the inclination angle is the major agent for depolarization, while fluctuations of magnetic field strength and density have an insignificant contribution. We propose and demonstrate that the mean inclination angle over a region of interest can be calculated from the polarization fraction in a strongly magnetized reference position, where $\overline{M_{\rm A}}_{,\bot}^2\ll1$. We test and show that the new method can trace the 3D magnetic fields in sub-Alfv\'enic, trans-Alfv\'enic, and moderately super-Alfv\'enic conditions ($0.4\lesssim M_{\rm A}\lesssim1.2$). We numerically quantify that the difference between the estimated inclination angle and actual inclination angle ranges from 0 to $20^\circ$ with a median value of $\le10^\circ$. - Open Access
- 8 February 2022
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 10, 769711
Integrated Analysis of MATH-Based Subtypes Reveals a Novel Screening Strategy for Early-Stage Lung Adenocarcinoma
Lung adenocarcinoma (LUAD) is a frequently diagnosed cancer type, and many patients have already reached an advanced stage when diagnosed. Thus, it is crucial to develop a novel and efficient approach to diagnose and classify lung adenocarcinoma at an early stage. In our study, we combined in silico analysis and machine learning to develop a new five-gene–based diagnosis strategy, which was further verified in independent cohorts and in vitro experiments. Considering the heterogeneity in cancer, we used the MATH (mutant-allele tumor heterogeneity) algorithm to divide patients with early-stage LUAD into two groups (C1 and C2). Specifically, patients in C2 had lower intratumor heterogeneity and higher abundance of immune cells (including B cell, CD4 T cell, CD8 T cell, macrophage, dendritic cell, and neutrophil). In addition, patients in C2 had a higher likelihood of immunotherapy response and overall survival advantage than patients in C1. Combined drug sensitivity analysis (CTRP/PRISM/CMap/GDSC) revealed that BI-2536 might serve as a new therapeutic compound for patients in C1. In order to realize the application value of our study, we constructed the classifier (to classify early-stage LUAD patients into C1 or C2 groups) with multiple machine learning and bioinformatic analyses. The 21-gene–based classification model showed high accuracy and strong generalization ability, and it was verified in four independent validation cohorts. In summary, our research provided a new strategy for clinicians to make a quick preliminary assisting diagnosis of early-stage LUAD and make patient classification at the intratumor heterogeneity level. All data, codes, and study processes have been deposited to Github and are available online.
- 8 February 2022
- Published by Frontiers Media SA in Frontiers in Cell and Developmental Biology
- Vol. 10, 769711
Open AccessIntegrated Analysis of MATH-Based Subtypes Reveals a Novel Screening Strategy for Early-Stage Lung Adenocarcinoma
Lung adenocarcinoma (LUAD) is a frequently diagnosed cancer type, and many patients have already reached an advanced stage when diagnosed. Thus, it is crucial to develop a novel and efficient approach to diagnose and classify lung adenocarcinoma at an early stage. In our study, we combined in silico analysis and machine learning to develop a new five-gene–based diagnosis strategy, which was further verified in independent cohorts and in vitro experiments. Considering the heterogeneity in cancer, we used the MATH (mutant-allele tumor heterogeneity) algorithm to divide patients with early-stage LUAD into two groups (C1 and C2). Specifically, patients in C2 had lower intratumor heterogeneity and higher abundance of immune cells (including B cell, CD4 T cell, CD8 T cell, macrophage, dendritic cell, and neutrophil). In addition, patients in C2 had a higher likelihood of immunotherapy response and overall survival advantage than patients in C1. Combined drug sensitivity analysis (CTRP/PRISM/CMap/GDSC) revealed that BI-2536 might serve as a new therapeutic compound for patients in C1. In order to realize the application value of our study, we constructed the classifier (to classify early-stage LUAD patients into C1 or C2 groups) with multiple machine learning and bioinformatic analyses. The 21-gene–based classification model showed high accuracy and strong generalization ability, and it was verified in four independent validation cohorts. In summary, our research provided a new strategy for clinicians to make a quick preliminary assisting diagnosis of early-stage LUAD and make patient classification at the intratumor heterogeneity level. All data, codes, and study processes have been deposited to Github and are available online.